PDCD1 and non-small cell lung carcinoma: PD-1 blockade and PD-L1 blockade largely showed similar efficacy, although the ORRs were ~5% higher with PD-1 blockade than with PD-L1 blockade in NSCLC, and results of PD-L1 blockade need to be validated in phase 3 studies.